News Image

NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

By Mill Chart

Last update: Apr 24, 2024

Uncover the hidden value in EXELIXIS INC (NASDAQ:EXEL) as our stock screening tool recommends it as an undervalued choice. NASDAQ:EXEL maintains a robust financial position and offers an attractive pricing perspective. Let's dig deeper into the analysis.

Valuation Analysis for NASDAQ:EXEL

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:EXEL boasts a 7 out of 10:

  • EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.21% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 97.09% of the companies listed in the same industry.
  • Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 95.38% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.40% of the companies in the same industry.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 46.47% in the coming years.

Profitability Analysis for NASDAQ:EXEL

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:EXEL, the assigned 7 is noteworthy for profitability:

  • With an excellent Return On Assets value of 7.06%, EXEL belongs to the best of the industry, outperforming 96.58% of the companies in the same industry.
  • EXEL has a better Return On Equity (9.18%) than 96.06% of its industry peers.
  • EXEL has a better Return On Invested Capital (5.31%) than 95.55% of its industry peers.
  • EXEL has a Profit Margin of 11.35%. This is amongst the best in the industry. EXEL outperforms 96.23% of its industry peers.
  • With an excellent Operating Margin value of 9.34%, EXEL belongs to the best of the industry, outperforming 95.55% of the companies in the same industry.
  • EXEL has a better Gross Margin (96.04%) than 96.92% of its industry peers.

Health Assessment of NASDAQ:EXEL

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:

  • An Altman-Z score of 7.35 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • EXEL's Altman-Z score of 7.35 is amongst the best of the industry. EXEL outperforms 83.73% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • EXEL has a Current Ratio of 3.34. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 3.30 indicates that EXEL has no problem at all paying its short term obligations.

Unpacking NASDAQ:EXEL's Growth Rating

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:EXEL has received a 5 out of 10:

  • The Earnings Per Share has grown by an nice 12.28% over the past year.
  • The Revenue has grown by 13.60% in the past year. This is quite good.
  • EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.47% yearly.
  • The Earnings Per Share is expected to grow by 30.94% on average over the next years. This is a very strong growth
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.

Check the latest full fundamental report of EXEL for a complete fundamental analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

EXELIXIS INC

NASDAQ:EXEL (5/3/2024, 7:00:01 PM)

After market: 21.9 0 (0%)

21.9

-0.22 (-0.99%)

EXEL News

News Image4 days ago - Market News VideoNotable Wednesday Option Activity: TMDX, WRB, EXEL
News Image5 days ago - Market News VideoExelixis (EXEL) Shares Cross Below 200 DMA
News Image5 days ago - The Motley FoolExelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

News Image5 days ago - InvestorPlaceEXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024

EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image5 days ago - BusinessInsiderEXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Exelixis (NASDAQ:EXEL) just reported results for the first quarter of 2024.Exel...

News Image5 days ago - Exelixis, Inc.Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
News Image9 days ago - InvestorPlaceThe Top 3 Biotech Stocks to Buy in April 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

News Image12 days ago - ChartmillTechnical Signals Point to a Possible Breakout for EXELIXIS INC.

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

News Image12 days ago - ChartmillNASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

News Image19 days ago - Exelixis, Inc.Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
News Imagea month ago - InvestorPlace3 Biotech Stocks to Buy on the Dip: March 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

News Imagea month ago - The Motley Fool4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

EXEL Links
Follow us for more